Effect of Genetic Polymorphism of CYP2C8 Enzyme on the Montelukast Therapy Responses in Iraqi Asthmatic Children

المؤلفون

  • Hasnaa Haider Mohammed Department of Pharmacology and Toxicology, College of Pharmacy, University of Kerbala, Kerbela, Iraq
  • Uday Abdul-Reda Department of Pharmacology and Toxicology, College of Pharmacy, University of Al-Ameed, Kerbala, Iraq
  • Hassan Mahmood Abo-Almaali Department of Clinical Laboratory Science, College of Pharmacy, University of Kerbala, Kerbala, Iraq

DOI:

https://doi.org/10.62472/kjps.v15.i24.146-155

الكلمات المفتاحية:

Montelukast، CYP2C8، Allele specific، Asthmatic children، ACT، IgE

الملخص

Background: Some reports show that the CYP2C8 enzyme plays an influential role in montelukast metabolism, and genetic polymorphism of CYP2C8 genes may influence therapeutic responses of asthmatic children to montelukast treatment.

Aim of the study:  The current study aimed to detect the effects of genetic polymorphism of the CYP2C8*1B (rs7909236) gene on montelukast response in asthmatic children.

Methods and Patients: An observational cross-sectional study was carried out in the respiratory clinic center in the Kerbala Teaching Hospital of Children from early October 2022 to late September 2023.

The trial included one hundred children older than six years old with asthma who had been previously diagnosed and were taking montelukast every day for at least one month. Alle-specific PCR patients out following DNA extraction to determine each patient's genotype to determine each patient's genotype. Total serum Ig E levels, Asthma Control Test (ACT), FEV1, and PEF of Pulmonary Function Tests were also measured.

Results: The distribution of CYP2C8*1B (rs 7909236) genetics polymorphism was found to be 74% for CC wild homozygous, 22% for CA mutants heterozygous, and 4% for mutants homozygous AA, according to the results of genetic amplification. Patients with wild-type and mutant genes do not significantly differ in serum total IgE, FEV1, PEF values, or ACT scores. Therefore, this polymorphism and montelukast responsiveness is predicted to be not significantly related (p value<0.05).

Conclusions: The montelukast respond and the CYP2C8*1B g.-271 G>A (rs7909236) genetic variation did not significantly associate.

التنزيلات

منشور

2024-09-12